

Special Issue

The Evolving Landscape of Contemporary Cancer Therapies

Message from the Guest Editor

A new era of cancer therapeutic modalities, including immunotherapies and targeted therapies, has led to a paradigm shift in cancer treatment, inducing effective and durable clinical responses for a significant number of patients suffering from various types of malignancy. Combinatorial treatments, including immune checkpoint inhibitors, adoptive cellular therapies, molecular targeted therapies, and cancer vaccines have overcome cancer heterogeneity, inducing resistance mechanisms, and thus reinforcing the impact of these novel cancer therapeutic approaches. The 9th Symposium on Advances in Cancer Immunology and Immunotherapy, which will be held on November 30–December 2 2023 in Athens, plans to address multidisciplinary issues related to cancer immunology and immunotherapy spanning basic and translational research with the ultimate aim to design the most effective cancer therapeutic strategies. The conference will feature world-renowned oncologists and researchers, who will provide their insights on the above topics, in an effort to enhance our understanding of tumor evolution and design-enhanced treatment strategies.

Guest Editor

Dr. Constantin N. Baxevanis

1. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
2. Flow Cytometry Unit, Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Ilisia, 15784 Athens, Greece

Deadline for manuscript submissions

closed (31 May 2025)



Onco

an Open Access Journal
by MDPI

Indexed in Scopus




mdpi.com/si/181080

Onco
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
onco@mdpi.com

[mdpi.com/journal/
onco](https://mdpi.com/journal/onco)





Onco

an Open Access Journal
by MDPI

Indexed in Scopus



[mdpi.com/journal/
onco](https://mdpi.com/journal/onco)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Constantin N. Baxevanis

1. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece

2. Flow Cytometry Unit, Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Ilisia, 15784 Athens, Greece

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.7 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2025).